The transmission of pathogenic agents by transfusion of cellular and protein products derived from blood is an ongoing and serious problem. The proposed studies are designed to evaluate both physical and chemical approaches for the inactivation of viruses in these products. Process methods will be selected initially on the basis of sterilization efficacy against easily quantifiable viruses, and of recovery of intact and functioning red cells, platelets, and plasma coagulation factors. After promising approaches have been identified, their efficiency in inactivating HIV and type B and non-A, non-B hepatitis viruses will be evaluated in tissue culture and in chimpanzees, respectively. Finally, demonstration lots of virus sterilized fresh frozen plasma, cryoprecipitate, and units of red blood cell and platelet concentrates will be prepared and evaluated clinically. The New York Blood Center is especially well suited to accomplish these goals because of its extensive research with blood borne viruses, its experience in developing and evaluating methods of virus inactivation applicable to purified protein derivatives, and because of the availability of our primate facility in Liberia. This project will further benefit from our supply of resource material; our laboratory, pilot plant, and components facilities; and our experience in handling and analyzing plasma proteins and blood components and in preparing experimental and licensed biologics for therapeutic use in humans.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL041221-03
Application #
3358837
Study Section
Special Emphasis Panel (SRC (19))
Project Start
1988-07-01
Project End
1992-06-30
Budget Start
1990-07-01
Budget End
1991-06-30
Support Year
3
Fiscal Year
1990
Total Cost
Indirect Cost
Name
New York Blood Center
Department
Type
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10065
Zmudzka, B Z; Strickland, A G; Beer, J Z et al. (1997) Photosensitized decontamination of blood with the silicon phthalocyanine Pc 4: no activation of the human immunodeficiency virus promoter. Photochem Photobiol 65:461-4
Margolis-Nunno, H; Bardossy, L; Robinson, R et al. (1997) Psoralen-mediated photodecontamination of platelet concentrates: inactivation of cell-free and cell-associated forms of human immunodeficiency virus and assessment of platelet function in vivo. Transfusion 37:889-95
Ben-Hur, E; Oetjen, J; Horowitz, B (1997) Silicon phthalocyanine Pc 4 and red light causes apoptosis in HIV-infected cells. Photochem Photobiol 65:456-60
Zhao, X J; Lustigman, S; Li, Y S et al. (1997) Structure-activity and mechanism studies on silicon phthalocyanines with Plasmodium falciparum in the dark and under red light. Photochem Photobiol 66:282-7
Smetana, Z; Malik, Z; Orenstein, A et al. (1997) Treatment of viral infections with 5-aminolevulinic acid and light. Lasers Surg Med 21:351-8
Ben-Hur, E; Barshtein, G; Chen, S et al. (1997) Photodynamic treatment of red blood cell concentrates for virus inactivation enhances red blood cell aggregation: protection with antioxidants. Photochem Photobiol 66:509-12
Lustigman, S; Ben-Hur, E (1996) Photosensitized inactivation of Plasmodium falciparum in human red cells by phthalocyanines. Transfusion 36:543-6
Ben-Hur, E; Moor, A C; Margolis-Nunno, H et al. (1996) The photodecontamination of cellular blood components: mechanisms and use of photosensitization in transfusion medicine. Transfus Med Rev 10:15-22
Ben-Hur, E; Horowitz, B (1996) Virus inactivation in blood. AIDS 10:1183-90
Gottlieb, P; Margolis-Nunno, H; Robinson, R et al. (1996) Inactivation of Trypanosoma cruzi trypomastigote forms in blood components with a Psoralen and Ultraviolet A light. Photochem Photobiol 63:562-5

Showing the most recent 10 out of 32 publications